Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Apr 15, 2024
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Dec 16, 2013
Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season
Dec 09, 2013
FDA Authorizes Expansion of Ampligen®/FluMist® Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses
Dec 04, 2013
Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers
Dec 02, 2013
Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies with Ampligen® as a Key Component
Nov 19, 2013
HEMISPHERX BIOPHARMA SPONSORS CHRONIC FATIGUE SYNDROME CONFERENCE AT MOUNT SINAI MEDICAL CENTER IN NEW YORK
Oct 18, 2013
Hemispherx Biopharma Reports on Annual Stockholder Meeting
Oct 03, 2013
Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration
Sep 18, 2013
Hemispherx Biopharma's 2013 Stockholder Annual Meeting Set
Sep 12, 2013
Natural Human Interferon (α-n3) is Active Against Both Wild-type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus
1
2
3
<<
<
>
>>
Privacy